Source-grounded facts extracted from bioAffinity Technologies, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
bioAffinity Technologies, Inc. reported first quarter ended March 31, 2026 results: revenue $1.4 million.
“Lung testing revenue increased approximately 114% to $361,000 , compared to $169,000 in the first quarter of 2025. ● Total consolidated revenue decreased approximately 27% to $1.4 million , compared to $1.9 million for the first quarter of 2025, resulting from the discontinuation of certain unprofitable pathology services in March 2025 to focus on higher margin”
bioAffinity Technologies, Inc.: Increased authorized shares of Common Stock from 100,000,000 to 350,000,000 and designated Series B Convertible Preferred Stock (effective 2025-08-13).
“On August 13, 2025, the Company filed a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Certificate of Amendment”) to increase the number of authorized shares of the Company’s Common Stock from 100,000,000 to 350,000,000.”
bioAffinity Technologies, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“ies will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on August 18, 2025. In addition, as of the date hereof, the Company has not regained compliance with the Continued Listing Equity Requirement. As a result and pursuant to Listing Rule 5810(d)(2), this deficiency now serves as an additional basis for delisting of the Company’s securities. The Company intends to submit an appeal to Nasdaq on August 14, 2025, which will stay the delisting and suspension of the Company’s securities pending the decision of the Panel. Hearings are typi”
bioAffinity Technologies, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“ies will be scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of business on August 18, 2025. In addition, as of the date hereof, the Company has not regained compliance with the Continued Listing Equity Requirement. As a result and pursuant to Listing Rule 5810(d)(2), this deficiency now serves as an additional basis for delisting of the Company’s securities. The Company intends to submit an appeal to Nasdaq on August 14, 2025, which will stay the delisting and suspension of the Company’s securities pending the decision of the Panel. Hearings are typi”
Stuart Diamond departed as Director at bioAffinity Technologies, Inc..
“On April 12, 2025, Stuart Diamond, a member of the board of directors (the “Board”) of bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), notified the Company of his decision not to stand for re-election at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).”
bioAffinity Technologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3”
J. Michael Edwards was appointed as Chief Financial Officer at bioAffinity Technologies, Inc..
“On October 4, 2024, the Board of Directors (the “Board”) of bioAffinity technologies, Inc. (the “Company”) appointed J. Michael Edwards, who has served as the Company’s Interim Chief Financial Officer, as a consultant, since September 2024, to serve as Chief Financial Officer of the Company, effective November 5, 2024.”
Michael Edwards was appointed as Interim Chief Financial Officer and Principal Accounting Officer at bioAffinity Technologies, Inc..
“the Board of Directors of the Company appointed, effective as of September 16, 2024, Michael Edwards, age 57, to serve as the Company’s Interim Chief Financial Officer and Principal Accounting Officer.”
Michael Dougherty resigned as Chief Financial Officer and Principal Accounting Officer at bioAffinity Technologies, Inc..
“Michael Dougherty notified bioAffinity Technologies, Inc. (the "Company") of his decision to resign from his position as the Company’s Chief Financial Officer and Principal Accounting Officer to pursue other opportunities.”
bioAffinity Technologies, Inc. reported the three months ended March 31, 2024 results: revenue $2.4 million, net income $2.1 million, EPS $0.21 per share. Guidance raised.
“First Quarter Financial Results Revenue for the first quarter of 2024 was $2.4 million, compared with $921 revenue for the prior-year period. The majority of the year-over-year increase is through the acquisition of Precision Pathology Laboratory Services. Revenue is primarily generated from patient service fees, including billing for CyPath ® Lung tests, with additional revenues generated from histology service fees and medical director fees. Research and development expenses were $394,000 for the first quarter of 2024, compared with $370,000 for the comparable period in 2023. The increase was primarily due to higher compensation costs for additional research personnel and higher R&D laboratory supply costs. Clinical development expenses were $49,000 for the first quarter of 2024, compared with $20,000 for the first quarter of 2023. The increase was primarily due to an increase in compensation costs and benefits from the addition of new clinical development personnel. Selling, general”
bioAffinity Technologies, Inc. reported the three and 12 months ended December 31, 2023 results: revenue $2.5 million, net income $7.9 million, EPS $0.91 per share.
“expanding our market to fulfill the promise of early cancer detection and treatment.” Fourth Quarter Financial Results Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period. Revenue was derived from sales and services of the Company’s commercial laboratory, Precision Pathology Laboratory Services,”
bioAffinity Technologies, Inc. entered into Securities Purchase Agreement with four institutional investors valued at aggregate gross proceeds of approximately $2.5 million (effective 2024-03-06).
“On March 6, 2024, bioAffinity Technologies, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with four institutional investors (the "Purchasers"), pursuant to which the Company will issue to the Purchasers, (i) in a registered direct offering, 1,600,000 shares of the Company’s common stock (the "Shares"), par value $0.007 per share ("Common Stock") and (ii) in a concurrent private placement, warrants to purchase an aggregate of 1,600,000 shares of Common Stock (the "Common Warrants") with an exercise price of $1.64.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.